Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kala Pharmaceuticals, Inc.    KALA

KALA PHARMACEUTICALS, INC.

(KALA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Kala Pharmaceuticals : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

share with twitter share with LinkedIn share with facebook
09/18/2020 | 05:06pm EDT

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to 7,000 shares of Kala Pharmaceuticals common stock to a new employee. The stock options were granted on September 15, 2020. The grant was approved by the Compensation Committee and made as an inducement material to the employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option award has an exercise price of $8.05 per share, the closing price of Kala Pharmaceuticals’ common stock on September 15, 2020. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. Vesting of the option award is subject to the employee’s continued service with Kala Pharmaceuticals through the applicable vesting dates.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a target action date under the Prescription Drug User Fee Act (PDUFA) set for October 30, 2020.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about KALA PHARMACEUTICALS, INC.
07:05aKALA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regu..
AQ
07:02aKALA PHARMACEUTICALS : Announces FDA Approval of EYSUVIS™ for the Short-Te..
BU
10/20KALA PHARMACEUTICALS : Reports Inducement Grant under NASDAQ Listing Rule 5635(4..
AQ
10/19KALA PHARMACEUTICALS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c..
BU
09/18KALA PHARMACEUTICALS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c..
BU
09/17KALA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
AQ
09/11KALA PHARMACEUTICALS : to Host Key Opinion Leader Symposium on Unmet Need in Dry..
AQ
09/10KALA PHARMACEUTICALS : to Host Key Opinion Leader Symposium on Unmet Need in Dry..
BU
09/08KALA PHARMACEUTICALS : to Present at Upcoming Investor Conferences in September
BU
08/06KALA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Conditi..
AQ
More news
Financials (USD)
Sales 2020 7,68 M - -
Net income 2020 -92,1 M - -
Net cash 2020 96,6 M - -
P/E ratio 2020 -4,42x
Yield 2020 -
Capitalization 433 M 433 M -
EV / Sales 2020 43,8x
EV / Sales 2021 7,54x
Nbr of Employees 136
Free-Float 99,4%
Chart KALA PHARMACEUTICALS, INC.
Duration : Period :
Kala Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 19,71 $
Last Close Price 7,72 $
Spread / Highest target 405%
Spread / Average Target 155%
Spread / Lowest Target 29,5%
EPS Revisions
Managers
NameTitle
Mark T. Iwicki Chairman, President & Chief Executive Officer
Todd Bazemore Chief Operating Officer
Mary E. Reumuth Chief Financial Officer, Controller & Treasurer
Romulus Kim Brazzell Chief Medical Officer
Hongming Chen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
KALA PHARMACEUTICALS, INC.109.21%433
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381